Advertisement

Rehabilitation and palliation of patients with prostatic cancer

Chapter
  • 757 Downloads
Part of the Collection de L’Académie Européenne de Médecine de Réadaptation book series (LACADEMIE)

Abstract

The chief aim of all medical, potentially curative follow-up care measures (recurrence prophylaxis, early detection and therapy of disease recurrence) is to lengthen survival time (fig. 1.3). The cancer disease thus represents the focus of curative follow-up care.

Keywords

Prostate Cancer Urinary Incontinence Bone Metastasis Pelvic Floor Erectile Dysfunction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliographie

  1. — Amarenco G, Chantraine A (edit) (2006) Les fonctions sphinctériennes. Springer ParisGoogle Scholar
  2. — Aspinal F, Hughes R, Higginson I et al. (2002) A user’s guide to the palliative care outcome scale. Palliative care & policy publications. Kings College, LondonGoogle Scholar
  3. — Barat M, Franchignoni F (2004) Assessment in physical medicine and rehabilitation. Maugeri Foundation Books, PI-ME Press PaviaGoogle Scholar
  4. — Bartsch HH, Delbrück H, Kruck P et al. (2000) Zur Prozessqualität in der onkologischen Rehabilitation. Rehabilitation 39; 355–8PubMedCrossRefGoogle Scholar
  5. — Bamias A, Kastritis E, Bamias C (2005) Osteonecrosis of the jaw in cancer after treatment with bisphophonates: Incidence and risk factors J Clin Oncol 23,34: 8580–7PubMedCrossRefGoogle Scholar
  6. — Barton D, Loprinzi CL (2004) Making sense of the evidence regarding nonhormonal treatments for hot flashes. Clin J Oncol Nurs 8,1: 39–42PubMedCrossRefGoogle Scholar
  7. — Bausewein C, Fegg M, Radbruch L et al. (2005) Validation and clinical application of the German version of the palliative care outcome. J Pain Symptom Manage 30: 51–62PubMedCrossRefGoogle Scholar
  8. — Bradley C, Oberst K, Schenk M (2006) Absenteeism from work: The experience of employed breast and prostate cancer patients in the months following diagnosis. Psychooncology 15,8: 739–47PubMedCrossRefGoogle Scholar
  9. — Bundesarbeitsgemeinschaft für Rehabilitation (BAR) (2004) Rahmenempfehlungen zur ambulanten onkologischen Rehabilitation. Schriftenreihe der Bundesarbeitsgemeinschaft für Rehabilitation, FrankfurtGoogle Scholar
  10. — Caliendo MD, Lee E, Queiroz R et al. (2001) Sclerotherapy with Use of Doxycycline after Percutaneous Drainage of Postoperative Lymphoceles. Journal of Vascular and Interventional Radiology 12: 73–7PubMedCrossRefGoogle Scholar
  11. — Carlsson C, Baigi A, Killander D et al. (2005) Motives for becoming and remaining member of patient associations. Support Care Cancer 20Google Scholar
  12. — Charlson M, Pompei P, Ales K et al. (1987) A new method for classifying prognostic comorbity in longitudinal studies. J Chronic Dis, 40: 373–83PubMedCrossRefGoogle Scholar
  13. — Chen A, Petrylak D (2004) Complications of Androgen Deprivation Therapy in Men with Prostate Cancer. Current Oncology Reports 2004, 6: 209–15CrossRefGoogle Scholar
  14. — Dahn JR, Penedo FJ, Gonzalez JS et al. (2004) Sexual functioning and quality of life after prostate cancer treatment: Considering sexual desire. Urology 63,2: 273–7PubMedCrossRefGoogle Scholar
  15. — Delbrück H, Schmid L, Bartsch H et al. (2000) Zur Ergebnisqualität in der onkologischen Rehabilitation. Rehabilitation 39: 359–62PubMedCrossRefGoogle Scholar
  16. — Ershler N (2003) Cancer: A disease of the elderly. J support Oncol 1,2: 5–10PubMedGoogle Scholar
  17. — Esper P, Redman BG (1999) Supportive care, pain management and quality of life in advanced prostate cancer. Urol Clin North Am 26: 375PubMedCrossRefGoogle Scholar
  18. — Finlay IG, Mason M, Shelley M (2005) Radioisotopes for the palliation of metastatic bone cancer: A systematic review. Lancet Oncol 6,6: 392–400PubMedCrossRefGoogle Scholar
  19. — Gilligan T, Kantoff P (2002) Chemotherapy for prostate cancer. Urology 60(suppl. 3A): 94–100PubMedCrossRefGoogle Scholar
  20. — Gray RE, Klotz LH (2004) Restoring sexual function in prostate cancer patients: An innovative approach. Can J Urol 11,3: 2285–9PubMedGoogle Scholar
  21. — Gontero P, Fontana F, Bagnasacco A et al. (2003) Is there an optimal time for intracavernous prostaglandin E1 rehabilitation following nonnerve sparing radical prostatectomy? Results from a hemodynamic prospective study. J Urology 169: 2166–9CrossRefGoogle Scholar
  22. — Haab, F, Trockman B, Zimmern P et al. (1997) Quality of life and continence assessment of the artificial urinary sphincter in men with minimum 3.5 years of follow-up. J Urology 158: 435–9CrossRefGoogle Scholar
  23. — Hamdy NA, Papapoulos SE (2001) The palliative management of skeletal metastases in prostate cancer: Use of bone-seeking radionuclides and bisphosphonatesGoogle Scholar
  24. — Hartsell WF, Scott CB, Brunner DW et al. (2005) Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 97,11: 798–804PubMedGoogle Scholar
  25. — Key TJ et al. (2004) Fruits and vegetables and prostate cancer: No association among 1104 cases in a prospective study of 130,544 men in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 109: 119–124PubMedCrossRefGoogle Scholar
  26. — Krupski T, Smith MR, Lee WC et al. (2004) Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 101,3: 541–9PubMedCrossRefGoogle Scholar
  27. — Lawton CA, Won M, Pilepich M et al. (1991) Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 21: 935–9PubMedGoogle Scholar
  28. — Lilleby W, Fossa SD, Waehre HR et al. (1999) Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1,43, 4: 735–43Google Scholar
  29. — Mason T (2005) Information needs of wives of men following prostatectomy. Oncol Nurs Forum 10,32, 3: 557–63CrossRefGoogle Scholar
  30. — Mathewson-Chapman M (1997) Pelvic muscle exercise/biofeedback for urinary incontinence after prostatectomy: An education program. J Cancer Educ 12,4: 218–23PubMedGoogle Scholar
  31. — McEwan AJ (2000) Use of radionuclides for the palliation of bone metastases. Semin Radiat Oncol 10,2: 103–14PubMedCrossRefGoogle Scholar
  32. — McGlynn B, Al-Saffar N, Begg H et al. (2004) Management of urinary incontinence following radical prostatectomy. Urol Nurse 24,6: 475–82Google Scholar
  33. — Montorsi F, Salonia A, Briganti A et al. (2005) Vardenifil for the treatment of erectile dysfunction: A critical review of the literature based on a personal clinical experience. Eur Urol 47,5: 612–21PubMedCrossRefGoogle Scholar
  34. — Nishimura K, Yamaguchi Y, Yamanaka M et al. (2005) Climacteric-Like Disorders in Prostate Cancer Patients Treated with LHRH Agonists. Arch of Andrology 51,1: 41–8CrossRefGoogle Scholar
  35. — Nilsson S, Strang P, Ginman C et al. (2005) Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. J Pain Symptom Manage 29,4: 352–7PubMedCrossRefGoogle Scholar
  36. — Pepper R, Pati J, Kaisary A (2004) The incidence and treatment of lymphoceles after radical retropubic prostatectomy: BJU International 95: 772–5CrossRefGoogle Scholar
  37. — Pisansky T (2005) External Beam Radiotherapy as Curative Treatment of Prostate Cancer. Mayo Clin Proc 80: 883–98PubMedCrossRefGoogle Scholar
  38. — Pomfret I, Haslam J (2002) To exercise or not to exercise? Journal of Community Nursing 16: 08Google Scholar
  39. — Potosky AL, Legler J, Albertsen PC et al. (2000) Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the prostate cancer outcomes study. J Natl Cancer Inst 92: 1582–92PubMedCrossRefGoogle Scholar
  40. — Potosky AL, Davis WW, Hoffman RM et al. (2004) Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: The Prostate Cancer Outcomes Study. J Natl Cancer Inst 96: 1358–67PubMedCrossRefGoogle Scholar
  41. — Prezioso D, Piccirillo G, Galasso R et al. Gynecomastia due to hormonte therapy for advanced prostate cancer. Tumouri 90,4: 410–5Google Scholar
  42. — Riechers FA (2004) Including partners into the diagnosis of prostate cancer: a review of the literature to provide a model of care. Urol Nurse 24,1: 22–9Google Scholar
  43. — Roth AJ, Rosenfeld B, Kornblith AB et al. (2003) The memorial anxiety scale for prostate cancer: Validation of a new scale to measure anxiety in men with prostate cancer. Cancer 97,11: 2910–8PubMedCrossRefGoogle Scholar
  44. — Roth A (2005) Improving Quality of Life: Psychiatric Aspects of Treating Prostate Cancer. Psychiatric Times Vol. XXII: 5Google Scholar
  45. — Saad F, Gleason DM et al. (2004) Long term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Inst 96: 879–82Google Scholar
  46. — Schmid L, Delbrück H, Bartsch H et al. (2000) Zur Strukturqualität in der onkologischen Rehabilitation. Rehabilitation, 39: 350–4PubMedCrossRefGoogle Scholar
  47. — Schover LR (2005) Sexuality and fertility after cancer. Hematology 1: 523CrossRefGoogle Scholar
  48. — Shahininan et al. (2005) N Engl J Med 352: 154–64CrossRefGoogle Scholar
  49. — Smith JJ, Barrett D (2002) Implantation of the artificial genito-urinary sphincter. In PC Walsh et al., eds., Campbell’s Urology, 8th ed., 2: 1187–94. Philadelphia: WB. Saunders.Google Scholar
  50. — Smith M et al. (2003) Randomised controlled trial of zolendronic acid to prevent boneloss in men receiving androgen deprivation therapy for non metastatic prostate cancer. The Journal of Urology, 169: 2008–12PubMedCrossRefGoogle Scholar
  51. — Stoeckli R, Keller U (2004) Nutritional fat and the risk of type 2 diabetes and cancer. Physiol Behav 83,4: 611–5PubMedCrossRefGoogle Scholar
  52. — Tanvetyanon T (2005) Long-term efficacy of zoledronic acid fort he prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 5,97, 1: 70–1Google Scholar
  53. — Yablon CM, Banner MP, Ramchandani P et al. (2004) Complications of prostate cancer treatment: Spectrum of imaging findings. Radiographics 24,suppl. 1: 181–94CrossRefGoogle Scholar
  54. — Yi Su, Davis B, Herman M et al. (2004) Prostate brachytherapy seed localization by analysis of multiple projections: Identifying and addressing the seed overlap problem. Medical Physics 31,5: 1277–87CrossRefGoogle Scholar
  55. — Van Kampen M, de Weerdt W, van Poppel H et al. (2000) Effect of pelvic-floor reeducation on duration and degree of incontinence after radical prostatectomy: A randomized controlled trial. Lancet 355: 98–102PubMedCrossRefGoogle Scholar
  56. — Watson T, Mock V (2004) Exercise as an intervention for cancer-related fatigue. Phys Ther 84: 736–43PubMedGoogle Scholar
  57. — Walsh PC, Marschke P, Ricker D et al. (2000) Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 55(1): 58–61PubMedCrossRefGoogle Scholar
  58. — Ward JF, Blute ML, Slezak J et al. (2003) The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170: 1872–6PubMedCrossRefGoogle Scholar
  59. — William K (2000) Chemotherapy for patients with advanced prostate carcinoma. A new option for therapy. Cancer 88: 3015–21CrossRefGoogle Scholar
  60. — Windsor PM, Nicol KF, Potter J (2004) A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma Cancer, 101,3: 550–7PubMedCrossRefGoogle Scholar
  61. — Zaak D, Hungerhuber E, Müller-Lisse U et al. (2003) Urological emergencies. Urologe (A) 42: 849–63CrossRefGoogle Scholar
  62. — Zeegers MP, Friesema IH, Goldbohm RA et al. (2004) A prospective study of occupation and prostate cancer risk. J Occup Environ Med 46,3: 271–9PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2007

Personalised recommendations